The project “Development and verification of the effectiveness of the new COVID-19 immunodiagnostic tool” prepared by the consortium of the Adam Mickiewicz University in Poznań and the Provincial Specialist Complex of Healthcare Institutions of Lung Diseases and Tuberculosis in Wolica received over PLN 2.6 million from the National Center for Research and Development.

As part of the pilot tests, at least 200 patients diagnosed with COVID-19 and 4,000 general patients will be tested. At the same time, the scientist will try to extend the diagnostic utility of the test, increase the sensitivity and specificity, reduce costs and increase the production scale of the test components.

The proposed test will be crucial for the validation of SARS-CoV-2 vaccines, and will be an important tool to determine their effectiveness. In addition, the serum of people with high levels of anti-SARS-CoV-2 antibodies can be used in the treatment of sick people.